News
All the latest news from Quadratech Diagnostics. If you would like to receive updates via our newsletter then please sign up here.
Showing Category: Haemostasis
UK NEQAS for Laboratory and Clinical Haemostasis 2025 Reflections
UK NEQAS for Laboratory and Clinical Haemostasis 2025: Key Takeaways and Reflections by Quadratech Diagnostics Team In June, we were delighted to sponsor UK NEQAS Blood Coagulation Annual Scientific Meeting in Sheffield. We truly valued the opportunity to meet with our existing customers and to welcome new participants interested in our diagnostic solutions. The two-day […]
Haemostasis Journal Club September 2025
Keep informed about evolving science and clinical practice with our compilation of the latest studies, guidelines, and perspectives in haemostasis. GUIDELINES Barrett WJ, Kaucher KA, Orpet RE, et al. Tranexamic acid in trauma: A joint position statement and resource document of NAEMSP, ACEP, and ACS-COT. J Trauma Acute Care Surg. 2025;99(3):357-363. doi:10.1097/TA.0000000000004727 Lier H, Goossen K, […]
Haemostasis Q3 2025 News
Our round-up of the latest developments from across the haemostasis industry for Q3 2025. REGULATORY Novo Nordisk’s Alhemo (concizumab-mtci, a tissue factor pathway inhibitor antagonist) injection received positive opinion by the EMA CHMP, recommending label expansion to include the treatment of severe haemophilia A and moderate or severe haemophilia B without inhibitors (25 Jul) Kedrion […]
Haemostasis Q2 2025 News
Our round-up of the latest developments from across the haemostasis industry for Q2 2025, including the latest data presentations at ISTH 2025. REGULATORY FDA approved Bayer’s Jivi (a recombinant extended half-life factor VIII concentrate) for use in paediatric patients 7 years of age and older with haemophilia A based on Alfa-PROTECT and PROTECT Kids trial […]
Come Meet Us at the UK NEQAS Blood Coagulation ASM at Stand 2!
COME MEET US We are delighted to announce we will be a proud sponsor and exhibitor at the upcoming UK NEQAS Blood Coagulation ASM (Annual Scientific Meeting) in Sheffield. We very much look forward to meeting those in attendance and will be happy to discuss our offering of diagnostic reagents and kits for the […]
Quadratech Diagnostics Launches QD-SUB-366 – Activated Protein C and FXI Chromogenic Substrate
We are delighted to announce the global launch of QD-SUB-366 – Activated Protein C and FXI Chromogenic Substrate, the first chromogenic substrate from our new QD-TECH range. Developed through close collaboration with leading scientists, clinicians, and ISO/FDA-registered European manufacturers, QD-TECH reagents are tailored for use in clinical laboratories, research centres, and the pharmaceutical industry. QD-SUB-366 […]
Haemostasis March 2025 News
Our round-up of the latest developments from across the haemostasis industry for March 2025. REGULATORY Genentech’s TNKase (tenecteplase, tissue plasminogen activator) was approved by the FDA for the treatment of acute ischemic stroke (AIS) in adults, administered as a single 5-second intravenous (IV) bolus (3 Mar) Sanofi / Alnylam’s Qfitlia (fitusiran, antithrombin RNAi) was approved by […]
Haemostasis April 2025 Journal Club
Keep informed about evolving science and clinical practice with our March 2025 compilation of the latest studies, guidelines, and perspectives in haemostasis. PERSPECTIVES & REVIEWS Ellsworth P, Chen SL, Jones LA, et al. Acquired hemophilia A: a narrative review and management approach in the emicizumab era. J Thromb Haemost. 2025;23(3):824-835. doi:10.1016/j.jtha.2024.09.04 Reyes Ruiz A, Bhale […]
Chromogenic Substrates in Haemostasis
Chromogenic substrates are small synthetic peptides which mimic the natural substrate of the enzyme and have a detector chromophore, typically para-nitroaniline (pNA), attached to the cleavage site. Enzymatic cleavage releases pNA and results in a colour change, which can be followed spectrophotometrically and is proportional to the activity of the enzyme. The concept of chromogenic […]
Haemostasis January & February 2025 News
Our round-up of the latest developments from across the haemostasis industry for January & February 2025. REGULATORY Star Therapeutics’ VGA039 (Protein S mAb) granted FDA Fast Track designation for the treatment of Von Willebrand disease (VWD) (7 Jan) Sobi / Sanofi’s Altuvoct (efanesoctocog alfa, recombinant Factor VIII) was authorised by MHRA to treat and prevent […]
Haemostasis March 2025 Journal Club
Keep informed about evolving science and clinical practice with our March 2025 compilation of the latest studies, guidelines, and perspectives in haemostasis. GUIDELINES Devreese KMJ, Bertolaccini ML, Branch DW, et al. An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. J […]
Quadratech Diagnostics launches Factor-X Activator RVV-X globally
We are delighted to announce a global launch of Factor-X Activator RVV-X (50U) as the latest addition to the Q-TOX range of high quality toxins, antigens, antibodies, and virus-like particles (VLPs). Q-TOX RVV-X is a highly purified Factor X activating enzyme prepared from the Russell Viper Venom (Daboia russelii). Q-TOX RVV-X is available for research […]
